Quick Answer
Acumen Pharmaceuticals, Inc. reported Cash and Equivalents of $53.99 million for fiscal year 2025.
Acumen Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $53.99M | +51.5% |
| 2024 | $35.63M | -46.7% |
| 2023 | $66.89M | -48.6% |
| 2022 | $130.10M | +6.5% |
| 2021 | $122.16M | +179.1% |
| 2020 | $43.78M | +568.1% |
| 2019 | $6.55M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $46.83M | +41.1% | +27.2% |
| June 30, 2025 | $36.81M | -45.8% | +22.1% |
| March 31, 2025 | $30.16M | -35.7% | -15.3% |
| December 31, 2024 | $35.63M | -46.7% | +7.4% |
| September 30, 2024 | $33.18M | -65.0% | -51.2% |
| June 30, 2024 | $67.95M | — | +44.8% |
| March 31, 2024 | $46.93M | — | -29.8% |
| December 31, 2023 | $66.89M | -48.6% | -29.5% |
- Acumen Pharmaceuticals, Inc. showed an increase of +51.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Acumen Pharmaceuticals, Inc.’s cash and equivalents has grown by 724.0% (from $6.55 million to $53.99 million).
- The most recent figure is from Acumen Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: